ClinicalTrials.gg
RecruitingNCT06771193RETRACEUpdated Jul 20, 2025

Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

An observational study in Cervical Cancer, Locally Advanced Cervical Cancer and Recurrent Cervical Cancer, sponsored by MSD Italia S.r.l.. Recruiting at 11 sites in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by MSD Italia S.r.l. (part of Merck & Co., Inc) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc — 3 open to participants now, 6 under way, 2 of them phase 3. Uterine Cervical Neoplasms · Merck & Co., Inc.

Started
2024
with 1 other
Observational
2 of 31
1 open now
Registered
28th of 31
by date

Among the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, this one is one of 2 that started in 2024, is one of 2 observational ones, and was the 28th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

3 of the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.

Read the detailed description

This is a multicenter, observational, retrospective study. The primary aim of this trial is to describe patients and disease characteristics, as well as treatment pattern of locally advanced and recurrent/metastatic cervical cancer (R/M and LACC) in Italy, through a retrospective data capture, from January 2018 to December 2021.

Eligible cervical cancer patients will be identified by reviewing medical records and physician notes (paper or electronic).

Disease will be defined as follow:

  • Locally advanced cervical cancer: a large tumour within the cervix (more than 4cm) or it has grown into the tissues around the cervix, but the cancer has not spread to other organs; usually includes stage 2B, 3 and 4A (FIGO staging)
  • Recurrent cervical cancer: local tumour regrowth or development of distant metastasis discovered 6 months or more after complete regression of the treatment (26)
  • Metastatic cervical cancer: cancer spreads beyond the pelvis to other parts of the body; usually defined as stage 4B (FIGO staging) Moreover, the patients' characteristics will be stratified as low risk and high risk for locally advanced cervical cancer and differences between their treatment partners will be reported.
03

Conditions studied

  • Cervical Cancer
  • Locally Advanced Cervical Cancer
  • Recurrent Cervical Cancer
  • Metastatic Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive patients who attend the Oncologic Clinics authorized to participate in the study, with a record of diagnosed cervical cancer, treated between January 2018 and December 2021, will be eligible for inclusion in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient (or their legally acceptable representatives) must have signed and dated the \& Privacy Form (ICF)
  • Age ≥18 years
  • Diagnosis of a cervical cancer
  • Locally advanced stage (not suitable for curative surgery) or recurrent or disease
  • Any treatment received between January 2018 and December 2021 for advanced disease

Exclusion criteria

Exclusion Criteria:

  • Patients participating in a pharmacological clinical trial for the treatment of advanced disease
  • Patients who participated in a clinical trial
  • Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The proportion of patients receiving each different treatment pattern of LA, recurrent, and metastatic CC (%)

    Baseline and demographic characteristics will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

  2. The proportion of patient with recurrence or dead after treatment and remission (%)

    Baseline and demographic characteristics will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

  3. Median time from remission to recurrence

    The study aim is to describe the time from curative intervention to recurrence (for patients who had a curative surgery). Time to recurrence will be calculated and represented using Kaplan-Meier curves and summarized using median with 95% confidence interval.

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

  4. Number of lines of treatment

    The aim of this analysis is to describe patients' treatment patterns in LA or R/M Cervical Cancer considering the high heterogeneity of treatment options in clinical setting and the lack of real-world data in Italy.

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

  5. The costs in terms of resources utilization associated to the different treatment patterns of LA, recurrent and metastatic CC

    Healthcare services for the present study include drug costs, general hospital costs (based on number of patient admissions and days of hospitalization, outpatients' visits, emergency access), specialist consultations and concomitant medications related to safety issue, radiological procedures, laboratory exams.

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

Secondary outcomes

  1. The proportion of patients who undergone screening program (%)

    Baseline characteristics such as adherence to a screening program, HPV subtype, and PD-L1 expression will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

  2. HPV subtype typization, if available

    Baseline characteristics such as adherence to a screening program, HPV subtype, and PD-L1 expression will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

  3. History of HPV related lesions (CIN 2+ lesion)

    Baseline characteristics such as adherence to a screening program, HPV subtype, and PD-L1 expression will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

  4. The proportion of patients with PD-L1 >1% and >50% (%)

    To describe the expression profile of PD-L1 (if available in archive pathology reports). Baseline characteristics such as adherence to a screening program, HPV subtype, and PD-L1 expression will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).

    Time frame: Retrospective data capture from Jan 2018 to Dec 2021

07

Study locations

10 of 11 sites recruiting
  • Oncologia Medica Policlinico Sant'Orsola Malpighi
    Bologna, Bologna, Italy
    Recruiting
  • Ginecologia ed Ostetricia A.O. Cannizzaro
    Catania, Catania 95126, Italy
    Recruiting
  • Oncologia Medica 1 IRCCS Ospedale Policlinico San Martino
    Genova, Genova 16132, Italy
    Recruiting
  • Unità di Ginecologia Oncologica Medica IRCCS Ospedale San Raffaele
    Milan, Milano 20132, Italy
    Recruiting
  • Unità Ostetricia, Ginecologia e Ginecologia Oncologica medica Humanitas San Pio X
    Milan, Milano 30159, Italy
    Recruiting
  • Oncologia A.O.U. di Modena - Policlinico
    Modena, Modena 41124, Italy
    Recruiting
  • U.O.S. Trattamenti Innovativi dell'utero Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale
    Naples, Napoli 80131, Italy
    Recruiting
  • UOC Oncologia Medica ed Ematologia Azienda Ospedaliera Universitaria Luigi Vanvitelli
    Naples, Napoli 80138, Italy
    Recruiting
  • IRCCS Centro di Riferimento Oncologico (CRO)
    Aviano, Pordenone 33081, Italy
    Recruiting
  • U.O.C. Ginecologia Oncologica Policlinico Agostino Gemelli
    Roma, Roma 00168, Italy
    Recruiting
  • UOC Oncologia Medica Ospedale Dell'Angelo - Mestre Azienda USL3 Serenissima
    Mestre, Venezia, Italy
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 13, 2025
StartActual
Dec 17, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06771193
Lead sponsor
MSD Italia S.r.l.
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Dec 17, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jul 20, 2025

Study contacts

Stefania Lopez
Contact
info.studiclinici@opisresearch.com
+39 03626331

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion